Two binary lifeline events that they keep pushing details and timelines on, Innoventure and CellHeal which are still ongoing. This stock basically a double call option on those events and any ensuing royalities/contract payments....
I do find it hilarious:
"Osteopore Q3 CY23 revenues grew 22% YoY to A$588,678....Building on our record-breaking Q2 CY23 with a strong Q3 CY23 puts Osteopore in a strong position for Q4 CY23".
Strong position?
No they don't. Make it $1.59 million and that statement might hold some credibility. Sales too little too late to an ever dwindling cash balance. Needs three to four million more cash from either of these deals beyond share issuance - think some investors may have forgotten that source from the 30% equity Innoventure deal.
Stating all of the obvious of course...
OSX Price at posting:
4.5¢ Sentiment: Buy Disclosure: Held
